SRRA stock: buy or sell?
November 15th, 2019
Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally.
Should I buy SRRA stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Sierra Oncology stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Sierra Oncology stock a buy?
Financial institutions and banks publish stock ratings everyday.Unfortunately, we couldn't detect any rating for SRRA stock for the last month.
SRRA stock analysis
Sierra Oncology shares collapsed -4.00% to $0.24 yesterday.
Sierra Oncology shares collapsed -4.00% to $0.24 yesterday. SRRA marked a lower low and a lower high in the short term, defining a downward trend. Climbing above $0.35 would break this short term down trend and open possibilities for reversing this situation.
Shares of Sierra Oncology ended this week at $0.24 and collapsed a scary -7.69%. Late October SRRA climbed an amazing 9.09% in just one week.
Sierra Oncology is now in fresh lows to find new supports after lossing the support. Since price and 40-weeks moving average lines crossed down late March, SRRA fell $-1.63 per share (-87.17%). Stocks under the 40-weeks moving average line are usually not recommended for average traders.
SRRA stock price history
SRRA IPO was on July 16th, 2015 at $28.68 per share1. Since then, SRRA stock sliced a -99.20%, with a yearly average of -24.80%.
1: Adjusted price after possible price splits or reverse-splits.
SRRA stock historical price chart
SRRA stock reached 52-week highs on March at $2.01, and all-time highs 2015-07-16 with a price of 33.75.
SRRA stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not found any price forecast for Sierra Oncology stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Sierra Oncology didn't meet the estimates of the experts and posted a rough EPS of $-0.19 per share when experts were expecting $-0.21.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to , last anual sales report draw of to million dollars. When comparing vs , , profit margin (that is, the net income divided by revenues) a to .
Quarterly financial resultsReported quarter income marked $-14.28 M with a profit margin of . Profit margin stayed stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Sierra Oncology sales marked a tight movement and stayed steady a nan%. Looking back to recent quarterly results, Sierra Oncology posted 7 negative quarters in a row.
Sierra Oncology ownershipWhen you are planning to invest in a stock, it's always worth to check its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Sierra Oncology, 1.38% of all outstanding shares are owned by its staff.
In case of Sierra Oncology stock, 67.14% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SRRA stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$17.9 M||$62.6 M||$191.1 M|
|Total shares||74.7 M||11.6 M||49.4 M|
|Float shares||60.6 M||5.8 M||41.4 M|
|- Institutional holdings (%)||67.1%||53.7%||72.8%|
|- Insider holdings (%)||1.4%||20.9%||0.2%|
|Shares in short selling||0.0%||0.0%||0.0%|
|Friday, November 15th, 2019|
|Day range||$0.23 - $0.28|
|Average true range||$0.03|
|50d mov avg||$0.35|
|100d mov avg||$0.42|
|200d mov avg||$0.93|
Sierra Oncology performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. In the following table, we compare Sierra Oncology performance to Champions Oncology and Pieris Pharmaceuticals: